
Barbara Bachler-Konetzki
Barbara received her PhD in Biomedicine and Biotechnology from the University of Veterinary Medicine in Vienna, Austria in collaboration with the Harvard Medical School / Dana-Farber Cancer Institute in Boston, USA where she focused on the profiling of protective anti-HIV antibody responses upon vaccination. After moving back to Europe, she continued to work on antibodies at MorphoSys, a biotech company based in Munich, Germany, well-known for the discovery and development of therapeutic antibodies using human antibody libraries by applying the in silico phage display technology. During this time, Barbara successfully discovered a novel acting therapeutic antibody, and progressed it all the way from concept to pre-clinical candidate nomination. In 2021, this molecule entered clinical phase 1 testing in immune oncology. Joining Evotec in 2018, she played a key role in the establishment of the streamlined hybridoma platform and the implementation of the ATX-Gx™ mice from Alloy as source of fully human antibodies. She is now leading a group of scientists and technicians supporting internal and external antibody programmes from target identification to lead candidate nomination.